Brief: Sio Gene Therapies Appoints David Nassif Interim CEO
31/01/2022 21:58
Jan 31 (Reuters) - Sio Gene Therapies Inc SIOX.O :
* SIO GENE THERAPIES INC SAYS DAVID NASSIF HAS BEEN
APPOINTED
INTERIM CHIEF EXECUTIVE OFFICER
* SIO GENE THERAPIES INC - PORTFOLIO PRIORITIZATION ALLOWS
COMPANY
TO FOCUS RESOURCES AND EXTENDS ESTIMATED CASH RUNWAY INTO SECOND
HALF OF 2023
* SIO GENE THERAPIES INC - RESIGNATION OF CURRENT CEO AND
BOARD
DIRECTOR PAVAN CHERUVU
* SIO GENE THERAPIES INC - COMPANY TO PRIORITIZE
INDUSTRY-LEADING
CLINICAL-STAGE PROGRAMS, AXO-AAV-GM1 AND AXO-AAV-GM2
* SIO GENE THERAPIES INC - TO TERMINATE AXO-LENTI-PD LICENSE
AGREEMENT WITH OXFORD BIOMEDICA FOR PARKINSON'S DISEASE
Source text for Eikon: ID:nGNX8ykrzC
Further company coverage: SIOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results